Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study

Constipation is the most common adverse event (AE) of opioid therapy. This multicenter, phase 2 study evaluated the efficacy and safety of linaclotide in treating opioid-induced constipation (OIC) in patients with chronic noncancer pain syndromes (NCT02270983). Adults with OIC (<3 spontaneous bow...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenner, Darren M., Argoff, Charles E., Fox, Susan M., Bochenek, Wieslaw, D'Astoli, Patricia, Blakesley, Rick E., Reasner, David S., O'Dea, Christopher R., Cash, Brooks D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170446/
https://www.ncbi.nlm.nih.gov/pubmed/32310620
http://dx.doi.org/10.1097/j.pain.0000000000001754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170446/
https://www.ncbi.nlm.nih.gov/pubmed/32310620
http://dx.doi.org/10.1097/j.pain.0000000000001754

Ejemplares similares